Featured Insights

  1. Value Of Multi-Indication Immunotherapies For The Treatment Of Autoimmune Diseases In The United States 6/12/2025

    As multi-indication therapies become more common, new research questions their value. A study for ISPOR 2025 reveals a potential misalignment between the price and value of these versatile treatments.

  2. Impact Of JCA And Project Orbis On The European Revenue Potential Of An Oncology Product 6/12/2025

    Contrary to concerns about price erosion, new analysis suggests Joint Clinical Assessment and Project Orbis will likely increase European oncology product revenue by enabling faster market uptake.

  3. Creating A Compliant And Scalable CGT Logistics Launch Plan 6/12/2025

    As cell and gene therapies advance to commercialization, biopharma companies face immense logistical hurdles. A customized, end-to-end strategy is crucial for ensuring product integrity and market success.

  4. Preparing For Change: Rare Disease Launches In The Era Of EU Health Technology Assessment (HTA) 5/9/2025

    Experts at Pharma 2025 discussed the impending EU Health Technology Assessment and its implications for rare disease product launches, highlighting key challenges and necessary organizational adaptations for the pharmaceutical industry.

  5. Harnessing AI: Revolutionizing Drug Discovery And Early Disease Detection 5/9/2025

    The power of data and algorithms is unlocking new frontiers in healthcare. Pharma 2025 discussions focused on AI's role in revolutionizing drug discovery and early detection.

  6. Navigating The Evolution Of EU Health Technology Assessment (HTA) Regulation 5/9/2025

    The future of pharmaceutical access in Europe is being shaped by the new EU HTA regulation. Insights from Pharma 2025, featuring Herbert Altmann and Alexander Natz, shed light on this pivotal shift.

  7. Exploring Payer Coverage Of Anti-Obesity Medications 4/14/2025

    Understanding payer strategies for anti-obesity drugs is crucial. A recent study investigated commercial formulary trends, confirming cost as a major barrier despite positive patient outcomes.

  8. Exploring Value-Based Contracting In Rare Diseases 4/14/2025

    How are payers using value-based contracts for costly rare disease therapies? Exploratory research sheds light on negotiation frequency, preferred contract types, and internal data management trends.

  9. 5 Questions On Exploring Healthcare Decision-Maker Sentiments 4/14/2025

    Research presented at AMCP 2025 uses natural language processing on decision-maker feedback to predict coverage. Learn about the surprising findings and next steps in this Q&A.

  10. Scientific Literature Reviews And AI's Potential For Evidence Synthesis 4/14/2025

    Scientific literature reviews are crucial for HEOR decision-making but notoriously slow. Explore how AI can potentially accelerate evidence synthesis while maintaining necessary scientific rigor.